Lonza nominates Juan Andres and Eric Drapé as independent Board Members

A four-drug regimen for newly diagnosed high-risk multiple myeloma induced high rates of sustained minimal residual disease (MRD) negativity regardless of transplant status, a German

Just two months af­ter earn­ing an­oth­er ap­proval for its block­buster blood can­cer drug Breyanzi, Bris­tol My­ers Squibb can add an ac­cel­er­at­ed ap­proval to the list,